SUBSEQUENT EVENTS	3 Months Ended
Mar. 31, 2013
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 10 - SUBSEQUENT EVENTS On April 3 and May 1, 2013, the Company made payments in the principal amount of $10,000 plus accrued interest on the October 1, 2012 Promissory Note. As of the date of this filing, the note and all related accrued interest payable is paid in full. On April 10 and May 9, 2013, the Company made payments in the principal amount of $10,000 each to the holder of the December 11, 2012 Promissory Note according to the terms of the note agreements. As of the date of this filing $20,000 in principal plus accrued interest remains due. On April 16 and May 14, 2013, the Company made payments in the principal amount of $20,000 plus accrued interest on the December 7, 2012 Promissory Note. As of the date of this filing, the note and all related accrued interest payable is paid in full. On April 17, 2013, the Company made payment of $5,000 to extend the due date of the June 21, 2011 Convertible Promissory Note to May 15, 2013. On May 15, 2013 an additional payment of $5,000 was made to extend the due date to June 15, 2013. In April of 2013, the Company received additional payments in the total amount of $41,000 in anticipation of the Series C preferred stock offering (see Note 7 – Stockholders’ Equity). The funds are being held in a segregated account. If the Series C Offering is not consummated, the Company will be obligated to return the advanced funds. On April 24, 2013, the Company received an additional $30,000 of funding under the May 30, 2012 Convertible Note. In April of 2013, the Company issued 350,000 shares of common stock to the holder of the May 30, 2012 Convertible Note in conversion of $13,802 of principal and interest. In April of 2013, the Company issued 300,000 shares of common stock to a consultant according to the terms of the engagement agreement. In April of 2013, the Company issued 500,000 shares of common stock to a consultant according to the terms of the engagement agreement. In May of 2013, the Company issued 288,603 shares of common stock to the holder of the May 30, 2012 Convertible Note in conversion of $12,525 of principal and interest. In May of 2013, the Company issued 1,948,051 shares of common stock to the holder of the 2012 Debentures in conversion of $75,000 of principal. In May of 2013, 1,029,334 shares of common stock were issued in the cashless exercise of 1,299,769 stock purchase warrants. On May 14, 2013, the Company executed a note payable agreement for up to $142,000 with interest accrued at 10% per annum. The note proceeds will be used to purchase additional CellerateRX inventory. The net revenues from the sale of the inventory will be used to pay the lender until all principal and accrued interest is paid in full. The Company has evaluated all subsequent events from the balance sheet date through the date of this filing and with the exception of the items mentioned above there are no events to disclose.

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2013

NOTE 10 - SUBSEQUENT EVENTS

On April 3 and May 1, 2013, the Company made payments in the principal amount of $10,000 plus accrued interest on the October 1, 2012 Promissory Note. As of the date of this filing, the note and all related accrued interest payable is paid in full.

On April 10 and May 9, 2013, the Company made payments in the principal amount of $10,000 each to the holder of the December 11, 2012 Promissory Note according to the terms of the note agreements. As of the date of this filing $20,000 in principal plus accrued interest remains due.

On April 16 and May 14, 2013, the Company made payments in the principal amount of $20,000 plus accrued interest on the December 7, 2012 Promissory Note. As of the date of this filing, the note and all related accrued interest payable is paid in full.

On April 17, 2013, the Company made payment of $5,000 to extend the due date of the June 21, 2011 Convertible Promissory Note to May 15, 2013. On May 15, 2013 an additional payment of $5,000 was made to extend the due date to June 15, 2013.

In April of 2013, the Company received additional payments in the total amount of $41,000 in anticipation of the Series C preferred stock offering (see Note 7 – Stockholders’ Equity). The funds are being held in a segregated account. If the Series C Offering is not consummated, the Company will be obligated to return the advanced funds.

On April 24, 2013, the Company received an additional $30,000 of funding under the May 30, 2012 Convertible Note.

In April of 2013, the Company issued 350,000 shares of common stock to the holder of the May 30, 2012 Convertible Note in conversion of $13,802 of principal and interest.

In April of 2013, the Company issued 300,000 shares of common stock to a consultant according to the terms of the engagement agreement.

In April of 2013, the Company issued 500,000 shares of common stock to a consultant according to the terms of the engagement agreement.

In May of 2013, the Company issued 288,603 shares of common stock to the holder of the May 30, 2012 Convertible Note in conversion of $12,525 of principal and interest.

In May of 2013, the Company issued 1,948,051 shares of common stock to the holder of the 2012 Debentures in conversion of $75,000 of principal.

In May of 2013, 1,029,334 shares of common stock were issued in the cashless exercise of 1,299,769 stock purchase warrants.

On May 14, 2013, the Company executed a note payable agreement for up to $142,000 with interest accrued at 10% per annum. The note proceeds will be used to purchase additional CellerateRX inventory. The net revenues from the sale of the inventory will be used to pay the lender until all principal and accrued interest is paid in full.

The Company has evaluated all subsequent events from the balance sheet date through the date of this filing and with the exception of the items mentioned above there are no events to disclose.